Re-examining the Meis Trial for Evidence of False-Positive Results

U.S. Food and Drug Administration (FDA)–approved 17α-hydroxyprogesterone caproate therapy is currently available to reduce recurrent preterm birth in the United States. This commentary reviews the original landmark Meis trial (“Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone...

Descripción completa

Detalles Bibliográficos
Autores principales: Sibai, Baha, Saade, George R., Das, Anita F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Contents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431135/
https://www.ncbi.nlm.nih.gov/pubmed/32769653
http://dx.doi.org/10.1097/AOG.0000000000003991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431135/
https://www.ncbi.nlm.nih.gov/pubmed/32769653
http://dx.doi.org/10.1097/AOG.0000000000003991

Ejemplares similares